Peritoneal Carcinomatosis research hub
6 indexed studies · 4 currently recruiting
- recruitingPHASE2
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
This study is testing a new, shorter way to give chemotherapy directly into the tummy after surgery for certain cancers that have spread to the tummy lining. It aims to see if this new method is easier and just as safe as a longer version.
Canada - recruiting
Molecular Characterisation of Colorectal Cancer Peritoneal Metastases
This study looks at changes in bowel cancer that has spread to the tummy lining (peritoneum). Researchers are examining stored tissue samples to understand why it spreads, identify future treatments, and improve care for patients in the UK.
United Kingdom - recruiting
Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)
This study looks for reasons why immunotherapy might not work for some people with advanced bowel cancer. It aims to find clues in tumour samples to help doctors choose the best treatment for each patient, so more people can benefit from life-saving medicines.
France - active not recruiting
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
This study looks at bowel cancer that has spread only to the liver. Researchers want to understand why some treatments work better for some people and to find new ways to predict how the cancer might behave and what treatments might be best.
Canada - active not recruiting
Registry Platform Colorectal Cancer
This study looks at how metastatic bowel cancer is treated in Germany. It tracks patients for up to three years to see which treatments are used and how they affect people's quality of life. It helps doctors understand common treatment paths.
Germany - not yet recruitingPHASE3
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
This study looks at treating advanced bowel cancer with FOLFIRI and cetuximab. We're testing if giving breaks between treatments works better than continuous treatment, aiming for fewer side effects and better quality of life. We're also using new blood tests to monitor progress.
Germany